Skip to main content
Premium Trial:

Request an Annual Quote

Marina Inks Partnership for Bladder Cancer Program


Marina Biotech said this week that it has signed an exclusive deal to work with Swiss biopharmaceuticals group Debiopharm to develop and commercialize its preclinical bladder cancer program.

Under the terms of the deal, the companies will work together to advance the RNAi drug candidate, but Debiopharm will have “full responsibility for the development and commercialization of any products arising from the partnership.” Marina stands to receive up to $25 million based on “predefined research and development milestones,” as well as royalties on product sales, the firms said.

Additional terms were not disclosed.

Bladder cancer had been Marina's lead program, with the company anticipating a phase I study as early as 2012 (GSN 13/25/2010). However, when it acquired Cequent Pharmaceuticals last year, that company's investigational treatment for familial adenomatous polyposis, which is expected to enter the clinic this year, moved to the forefront (GSN 11/18/2010).

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.